Catherine Madigan
Directeur Technique/Scientifique/R&D chez SYNDAX PHARMACEUTICALS, INC.
Fortune : 696 244 $ au 31/05/2024
Profil
Catherine Madigan is currently the Chief Medical Officer at Syndax Pharmaceuticals, Inc. She previously worked as the Senior Medical Director at Alnylam Pharmaceuticals, Inc. and as the Vice President & Head-Clinical Development at Syros Pharmaceuticals, Inc. Dr. Madigan completed her undergraduate degree at Dartmouth College and obtained her doctorate degree from Keck School of Medicine of USC.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/03/2024 | 36 131 ( 0,04% ) | 696 244 $ | 31/05/2024 |
Postes actifs de Catherine Madigan
| Sociétés | Poste | Début |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/03/2022 |
Anciens postes connus de Catherine Madigan
| Sociétés | Poste | Fin |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
| SYROS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Catherine Madigan
| Dartmouth College | Undergraduate Degree |
| Keck School of Medicine of USC | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| SYROS PHARMACEUTICALS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
